Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Jazz Pharmaceuticals plc - Ordinary Shares
(NQ:
JAZZ
)
109.92
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharmaceuticals plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz
July 01, 2025
ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options
Via
Benzinga
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
June 13, 2025
JAZZ Pharmaceuticals (NASDAQ:JAZZ) is an undervalued biopharma stock with strong profitability, reasonable financial health, and steady growth, making it a candidate for value investors.
Via
Chartmill
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
June 03, 2025
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.
Via
Benzinga
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts
June 03, 2025
Via
Benzinga
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
May 22, 2025
Jazz Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and reasonable growth, making it a potential pick for value investors.
Via
Chartmill
Earnings Scheduled For May 6, 2025
May 06, 2025
Via
Benzinga
Preview: Jazz Pharmaceuticals's Earnings
May 05, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts
March 05, 2025
Via
Benzinga
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook
May 19, 2025
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s...
Via
StockStory
Topics
World Trade
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
May 13, 2025
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Jazz Pharmaceuticals (NASDAQ:JAZZ) Misses Q1 Sales Targets
May 06, 2025
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s...
Via
StockStory
Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q1 Results Tomorrow
May 05, 2025
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results tomorrow after market close. Here’s what to expect.
Via
StockStory
Topics
Artificial Intelligence
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
May 05, 2025
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow afternoon. Here’s what to look for.
Via
StockStory
Despite its impressive fundamentals,JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) remains undervalued.
May 01, 2025
When you look at JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock
May 01, 2025
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock
Via
Chartmill
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
April 28, 2025
Jazz Pharmaceuticals currently trades at $109.85 per share and has shown little upside over the past six months, posting a small loss of 1.4%.
Via
StockStory
3 Small-Cap Stocks in the Doghouse
April 23, 2025
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...
Via
StockStory
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
April 17, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Where Jazz Pharmaceuticals Stands With Analysts
April 10, 2025
Via
Benzinga
3 Value Stocks Skating on Thin Ice
March 19, 2025
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...
Via
StockStory
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
March 18, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals.
March 15, 2025
JAZZ PHARMACEUTICALS PLC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:JAZZ showcases decent financial health and profitability, coupled with an attractive price.
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
March 11, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday
March 10, 2025
Via
Benzinga
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
March 06, 2025
Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.
Via
Benzinga
Topics
Earnings
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX
March 05, 2025
The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility.
Via
Talk Markets
Topics
Stocks / Equities
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
March 05, 2025
Jazz Pharmaceuticals will add dordaviprone, a potential treatment for a rare brain tumor, to its growing oncology pipeline.
Via
Benzinga
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
March 05, 2025
From
Chimerix, Inc.; Jazz Pharmaceuticals plc
Via
GlobeNewswire
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs
March 05, 2025
Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.
Via
Investor's Business Daily
3 Small-Cap Stocks Skating on Thin Ice
March 04, 2025
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.